FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2056531751> ?p ?o ?g. }

• W2056531751 endingPage "1233" @default.
• W2056531751 startingPage "1220" @default.
• W2056531751 abstract "No AccessJournal of UrologyCLINICAL UROLOGY: Review Article1 Oct 2001GENE THERAPY FOR PROSTATE CANCER: CURRENT STATUS AND FUTURE PROSPECTS K.J. HARRINGTON, C. SPITZWEG, A.R. BATEMAN, J.C. MORRIS, and R.G. VILE K.J. HARRINGTONK.J. HARRINGTON More articles by this author , C. SPITZWEGC. SPITZWEG More articles by this author , A.R. BATEMANA.R. BATEMAN More articles by this author , J.C. MORRISJ.C. MORRIS More articles by this author , and R.G. VILER.G. VILE More articles by this author View All Author Informationhttps://doi.org/10.1016/S0022-5347(05)65742-4AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: Locally advanced, relapsed and metastatic prostate cancer has a dismal prognosis with conventional therapies offering no more than palliation. In recent years advances achieved in understanding the molecular biology of cancer have afforded clinicians and scientists the opportunity to develop a range of novel genetic therapies for this disease. Materials and Methods: We performed a detailed review of published reports of gene therapy for prostate cancer. Particular emphasis was placed on recent developments in the arena of nonviral (plasmid DNA, DNA coated gold particles, liposomes and polymer DNA complexes) and viral (adenovirus, retrovirus, adeno-associated virus, herpes virus and pox virus) vectors. Therapeutic strategies were categorized as corrective, cytoreductive and immunomodulatory gene therapy for the purpose of data analysis and comparison. Results: Locoregional administration of nonviral and viral vectors can yield impressive local gene expression and therapeutic effects but to our knowledge no efficient systemically delivered vector is available to date. Corrective gene therapy to restore normal patterns of tumor suppressor gene (p53, Rb, p21 and p16) expression or negate the effect of mutated tumor promoting oncogenes (ras, myc, erbB2 and bcl-2) have efficacy in animal models but this approach suffers from the fact that each cancer cell must be targeted. A wide variety of cytoreductive strategies are under development, including suicide, anti-angiogenic, radioisotopic and pro-apoptotic gene therapies. Each approach has strengths and weaknesses, and may best be suited for use in combination. Immunomodulatory gene therapy seeks to generate an effective local immune response that translates to systemic antitumor activity. Currently most studies involve immunostimulatory cytokine genes, such as granulocyte-macrophage colony-stimulating factor, or interleukin-2 or 12. Conclusions: Various therapeutic genes have proved activity against prostate cancer in vitro and in vivo. However, the chief challenge facing clinical gene therapy strategies is the lack of efficient gene delivery by local and systemic routes. For the foreseeable future vector development may remain a major focus of ongoing research. Despite this caveat it is anticipated that gene therapy approaches may significantly contribute to the management of prostate cancer in the future. References 1 : Prostate-specific membrane antigen and other prostatic tumor markers on the horizon. Urol Clin North Am1997; 24: 439. Google Scholar 2 : Identification of a positive regulatory element responsible for tissue-specific expression of prostate-specific antigen. Cancer Res1997; 57: 495. Google Scholar 3 : Relative activity and specificity of promoters from prostate-expressed genes. Prostate1998; 35: 18. Google Scholar 4 : Development of prostate-specific antigen promoter-based gene therapy for androgen-independent human prostate cancer. J Urol1998; 160: 220. Link, Google Scholar 5 : Prostate-specific antigen (PSA) promoter-driven androgen-inducible expression of sodium iodide symporter in prostate cancer cell lines. Cancer Res1999; 59: 2136. Google Scholar 6 : In vivo expression of prostate-specific adenoviral vectors in a canine model. Cancer Gene Ther1999; 6: 456. Google Scholar 7 : Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: construction and testing of a tissue-specific adenovirus vector. Cancer Res2000; 60: 334. Google Scholar 8 : Prostate-specific suicide gene therapy using the prostate-specific membrane antigen promoter and enhancer. Prostate2000; 45: 149. Google Scholar 9 : Development of a new plasmid vector with PSA-promoter and enhancer expressing tissue-specificity in prostate carcinoma cell lines. Anticancer Res2000; 20: 417. Google Scholar 10 : Transcriptionally regulated adenoviruses for prostate-specific gene therapy. World J Urol2000; 18: 93. Google Scholar 11 : Osteocalcin-directed gene therapy for prostate-cancer bone metastasis. World J Urol2000; 18: 102. Google Scholar 12 : Gene therapy: promises, problems and prospects. Nature1997; 389: 239. Google Scholar 13 : Targeting of cytokine gene expression to malignant melanoma cells using tissue specific promoter sequences. Ann Oncol1994; 5: 59. Google Scholar 14 : In vitro and in vivo transfection of plasmid DNA in the Dunning prostate tumor R3327-AT1 is enhanced by focused ultrasound. Gene Ther2000; 7: 1516. Google Scholar 15 : Direct gene transfer to mouse melanoma by intratumor injection of free DNA. Gene Ther1996; 3: 542. Google Scholar 16 : DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc Natl Acad Sci USA1993; 90: 11478. Google Scholar 17 : In vivo cytokine gene transfer by gene gun reduces tumor growth in mice. Proc Natl Acad Sci USA1995; 92: 2889. Google Scholar 18 : Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci USA1987; 84: 7413. Google Scholar 19 : Efficient gene transfer with adeno-associated virus-based plasmids complexed to cationic liposomes for gene therapy of human prostate cancer. Cancer Res1995; 55: 2366. Google Scholar 20 : Cationic lipid-mediated gene transfer: current concepts. Curr Opin Molec Ther1999; 1: 158. Google Scholar 21 : Nonviral gene therapy: promises and challenges. Gene Ther2000; 7: 31. Google Scholar 22 : Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett1990; 268: 235. Google Scholar 23 : Sterically stabilized liposomes: Improvements in pharmacokinetics and antitumour therapeutic efficacy. Proc Natl Acad Sci USA1991; 88: 11460. Google Scholar 24 : Sterically stabilised liposomes in cancer therapy and gene delivery. Curr Opin Molec Ther1999; 1: 177. Google Scholar 25 : Phase I study of direct intralesional gene transfer of HLA-B7 into metastatic renal carcinoma lesions. Clin Cancer Res1999; 5: 2766. Google Scholar 26 : Immunotherapy of advanced malignancy by direct gene transfer of an interleukin-2 DNA/DMRIE/DOPE lipid complex: phase I/II experience. J Clin Oncol1999; 17: 3313. Google Scholar 27 : Factors affecting blood clearance and in vivo distribution of polyelectrolyte complexes for gene delivery. Gene Ther1999; 6: 643. Google Scholar 28 : A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc Natl Acad Sci USA1995; 92: 7297. Google Scholar 29 : Tracking the intracellular path of poly(ethylenimine)/DNA complexes for gene delivery. Proc Natl Acad Sci USA1999; 96: 5177. Google Scholar 30 : PEGylated DNA/transferrin-PEI complexes: reduced interaction with blood components, extended circulation in blood and potential for systemic gene delivery. Gene Ther1999; 6: 595. Google Scholar 31 : In vitro and in vivo gene delivery mediated by a synthetic polycationic amino polymer. Nat Biotechnol1997; 15: 462. Google Scholar 32 : Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism. J Virol1996; 70: 6839. Google Scholar 33 : Reovirus therapy of tumors with activated Ras pathway. Science1998; 282: 1332. Google Scholar 34 : Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus. Gene Ther1999; 6: 63. Google Scholar 35 : Evaluation of recombinant alphaviruses as vectors in gene therapy. Gene Ther2000; 7: 472. Google Scholar 36 : Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med2000; 6: 821. Google Scholar 37 : Retroviral vectors. Curr Top Microbiol Immunol1992; 158: 1. Google Scholar 38 : In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science1996; 272: 263. Google Scholar 39 : Development and application of adenoviral vectors for gene therapy of cancer. Cancer Gene Ther1999; 6: 113. Google Scholar 40 : Strategies to adapt adenoviral vectors for targeted delivery. Ann N Y Acad Sci1999; 886: 158. Google Scholar 41 : The dual impact of coxsackie and adenovirus receptor expression on human prostate cancer gene therapy. Cancer Res2000; 60: 5031. Google Scholar 42 : The origin of adenovirus DNA replication: minimal DNA sequence requirement in vivo. EMBO J1985; 4: 421. Google Scholar 43 : An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science1996; 274: 373. Google Scholar 44 : Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520 (ONYX-015). Nat Med2000; 6: 1128. Google Scholar 45 : ONYX-015: clinical data are encouraging. Nat Med1998; 4: 1341. Google Scholar 46 : Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res1997; 57: 2559. Google Scholar 47 : The addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts. Cancer Res1999; 59: 4200. Google Scholar 48 : Evaluation of the biodistribution, persistence, toxicity, and potential of germ-line transmission of a replication-competent human adenovirus following intraprostatic administration in the mouse. Mol Ther2000; 1: 263. Google Scholar 49 : Adeno-associated viral vectors. In: Gene Therapy Technologies, Applications and Regulations From Laboratory to Clinic. Edited by . Chichester, United Kingdom: John Wiley & Sons1999. Google Scholar 50 : Engineering herpes simplex virus vectors for gene transfer to neurons. Nat Med1997; 3: 357. Google Scholar 51 : HSV-1 amplicon vector: simplicity and versatility. Mol Ther2000; 2: 9. Google Scholar 52 : Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science1991; 252: 854. Google Scholar 53 : Antitumor activity and reporter gene transfer into rat brain neoplasms inoculated with herpes simplex virus vectors defective in thymidine kinase or ribonucleotide reductase. Gene Ther1994; 1: 323. Google Scholar 54 : An oncolytic herpes simplex virus type 1 selectively destroys diffuse liver metastases from colon carcinoma. FASEB J2000; 14: 301. Google Scholar 55 : Oncolytic viruses as novel anticancer agents: turning one scourge against another. Expert Opin Investig Drugs2000; 9: 311. Google Scholar 56 : Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther2000; 7: 859. Google Scholar 57 : Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med1995; 1: 938. Google Scholar 58 : Intravesical and intravenous therapy of human bladder cancer by the herpes vector G207. Hum Gene Ther2000; 11: 1683. Google Scholar 59 : Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207. Hum Gene Ther1999; 10: 2237. Google Scholar 60 : Disabled infectious single-cycle herpes simplex virus as an oncolytic vector for immunotherapy of colorectal cancer. Hum Gene Ther1999; 10: 2757. Google Scholar 61 : Tumor-specific gene delivery using recombinant vaccinia virus in a rabbit model of liver metastases. J Natl Cancer Inst1999; 91: 1744. Google Scholar 62 : Systemic administration of a recombinant vaccinia virus expressing the cytosine deaminase gene and subsequent treatment with 5-fluorocytosine leads to tumor-specific gene expression and prolongation of survival in mice. Cancer Res1999; 59: 3396. Google Scholar 63 : Vaccinia as a vector for tumor-directed gene therapy: biodistribution of a thymidine kinase-deleted mutant. Cancer Gene Ther2000; 7: 66. Google Scholar 64 : Replication-restricted vaccinia as a cytokine gene therapy vector in cancer: persistent transgene expression despite antibody generation. Cancer Gene Ther2000; 7: 663. Google Scholar 65 : Cancer gene therapy using tumor cells infected with recombinant vaccinia virus expressing GM-CSF. Hum Gene Ther1996; 7: 1853. Google Scholar 66 : Effect of canarypox virus (ALVAC)-mediated cytokine expression on murine prostate tumor growth. J Natl Cancer Inst1997; 89: 428. Google Scholar 67 : Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma. Cancer Gene Ther1999; 6: 409. Google Scholar 68 : Phase I study in cancer patients of a replication-defective avipox recombinant vaccine that expresses human carcinoembryonic antigen. J Clin Oncol1999; 17: 332. Google Scholar 69 : Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas. Clin Cancer Res2000; 6: 2219. Google Scholar 70 : A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin Cancer Res2000; 6: 1632. Google Scholar 71 : Viral vector delivery in solid-state vehicles: gene expression in a murine prostate cancer model. J Natl Cancer Inst2000; 92: 403. Google Scholar 72 : Cancer. p53, guardian of the genome. Nature1992; 358: 15. Google Scholar 73 : p53-Dependent cell cycle control: response to genotoxic stress. Semin Cancer Biol1998; 8: 325. Google Scholar 74 : p53 Oncogene mutations in human prostate cancer specimens. J Urol1994; 151: 492. Link, Google Scholar 75 : p53 Abnormalities in primary prostate cancer: single-strand conformation polymorphism analysis of complementary DNA in comparison with genomic DNA. Cooperative Prostate Network. J Natl Cancer Inst1997; 89: 66. Google Scholar 76 : p53 In prostate cancer: frequent expressed transition mutations. J Natl Cancer Inst1994; 86: 926. Google Scholar 77 : In vivo gene therapy with p53 or p21 adenovirus for prostate cancer. Cancer Res1995; 55: 5151. Google Scholar 78 : Adenovirus-mediated wild-type p53 expression induces apoptosis and suppresses tumorigenesis of prostatic tumor cells. Cancer Res1995; 55: 4210. Google Scholar 79 : Molecular therapy with recombinant p53 adenovirus in an androgen-independent, metastatic human prostate cancer model. Hum Gene Ther1996; 7: 1683. Google Scholar 80 : Suppression of primary tumor growth and the progression to metastasis with p53 adenovirus in human prostate cancer. J Urol2000; 164: 814. Abstract, Google Scholar 81 : Inhibition of the growth of pre-established subcutaneous tumor nodules of human prostate cancer cells by single injection of the recombinant adenovirus p53 expression vector. Int J Cancer1997; 71: 377. Google Scholar 82 : Adenovirus-mediated p53 gene therapy has greater efficacy when combined with chemotherapy against human head and neck, ovarian, prostate, and breast cancer. Cancer Chemother Pharmacol1999; 44: 143. Google Scholar 83 : Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J Natl Cancer Inst1999; 91: 763. Google Scholar 84 : Ad5CMVp53 gene therapy for locally advanced prostate cancer: where do we stand?. World J Urol2000; 18: 121. Google Scholar 85 : Retinoblastoma gene mutations in primary human prostate cancer. Prostate1995; 27: 314. Google Scholar 86 : Alterations of the retinoblastoma gene in clinically localized, stage B prostate adenocarcinomas. Hum Pathol1996; 27: 28. Google Scholar 87 : Enhanced tumor suppressor gene therapy via replication-deficient adenovirus vectors expressing an N-terminal truncated retinoblastoma protein. Cancer Res1996; 56: 2245. Google Scholar 88 : Adenovirus-mediated retinoblastoma gene therapy suppresses spontaneous pituitary melanotroph tumors in Rb± mice. Nat Med1996; 2: 1316. Google Scholar 89 : RB-mediated suppression of spontaneous multiple neuroendocrine neoplasia and lung metastases in Rb± mice. Proc Natl Acad Sci USA1999; 96: 3916. Google Scholar 90 : Prognostic value and expression of p21(waf1/cip1) protein in prostate cancer. Prostate1999; 39: 8. Google Scholar 91 : Overexpression of the cyclin-dependent kinase inhibitor p16 is associated with tumor recurrence in human prostate cancer. Clin Cancer Res1999; 5: 977. Google Scholar 92 : Prognostic significance of p16 and CDK4 proteins in localized prostate carcinoma. Cancer2000; 88: 416. Google Scholar 93 : Adenoviral vector containing wild-type p16 suppresses prostate cancer growth and prolongs survival by inducing cell senescence. Cancer Gene Ther2000; 7: 360. Google Scholar 94 : p16/MTS1/INK4A suppresses prostate cancer by both pRb dependent and independent pathways. Oncogene2000; 19: 1297. Google Scholar 95 : Adenovirus p16 gene therapy for prostate cancer. World J Urol2000; 18: 111. Google Scholar 96 : Role of adhesion molecules in bladder cancer: an important part of the jigsaw. Urology1999; 53: 428. Google Scholar 97 : Application of a tumor suppressor (C-CAM1)-expressing recombinant adenovirus in androgen-independent human prostate cancer therapy: a preclinical study. Cancer Res1995; 55: 2831. Google Scholar 98 : Schedule-dependence of C-CAM1 adenovirus gene therapy in a prostate cancer model. Anticancer Res1999; 19: 337. Google Scholar 99 : Tumor-suppressive activity of CD66a in prostate cancer. Cancer Gene Ther1999; 6: 313. Google Scholar 100 : Suppression of prostate cancer invasive potential and matrix metalloproteinase activity by E-cadherin transfection. Cancer Res1999; 59: 3552. Google Scholar 101 : Adenovirus-mediated expression of PML suppresses growth and tumorigenicity of prostate cancer cells. Cancer Res1997; 57: 1868. Google Scholar 102 : Inhibition of growth of malignant rat prostate tumor cells by restoration of fibroblast growth factor receptor 2. Cancer Res1998; 58: 1509. Google Scholar 103 : Growth inhibition of prostate cancer by an adenovirus expressing a novel tumor suppressor gene, pHyde. Cancer Res2000; 60: 4419. Google Scholar 104 : Comparison of ras activation in prostate carcinoma in Japanese and American men. Prostate1997; 30: 53. Google Scholar 105 : Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. Cancer Res1997; 57: 524. Google Scholar 106 : Overexpression of her-2/neu in human prostate cancer and benign hyperplasia. Cancer Lett1996; 99: 185. Google Scholar 107 : Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res1992; 52: 6940. Google Scholar 108 : Antiproliferative effects of c-myc antisense oligonucleotide in prostate cancer cells: a novel therapy in prostate cancer. Urology1997; 50: 1007. Google Scholar 109 : Antisense c-myc retroviral vector suppresses established human prostate cancer. Hum Gene Ther1998; 9: 747. Google Scholar 110 : Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model. Clin Cancer Res1999; 5: 2891. Google Scholar 111 : Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bcl-2 oligodeoxynucleotides. J Natl Cancer Inst2000; 92: 34. Google Scholar 112 : Suppression of various human tumor cell lines by a dominant negative H-ras mutant. Gene Ther1994; 1: 403. Google Scholar 113 : Antitumor activity of a C-raf antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted subcutaneously into nude mice. Clin Cancer Res1997; 3: 1179. Google Scholar 114 : Prostate-specific antigen promoter driven gene therapy targeting DNA polymerase-alpha and topoisomerase II alpha in prostate cancer. Anticancer Res1996; 16: 1805. Google Scholar 115 : Design and testing of ribozymes for cancer gene therapy. Adv Exp Med Biol2000; 465: 293. Google Scholar 116 : Development of a hammerhead ribozyme against bcl-2. I. Preliminary evaluation of a potential gene therapeutic agent for hormone-refractory human prostate cancer. Prostate1997; 32: 246. Google Scholar 117 : A recombinant defective adenoviral agent expressing anti-bcl-2 ribozyme promotes apoptosis of bcl-2-expressing human prostate cancer cells. Int J Cancer1999; 82: 846. Google Scholar 118 : Effective reversal of a transformed phenotype by retrovirus-mediated transfer of a ribozyme directed against mutant N-ras. Gene Ther1998; 5: 227. Google Scholar 119 : A novel gene therapy strategy for elimination of prostate carcinoma cells from human bone marrow. Hum Gene Ther1997; 8: 157. Google Scholar 120 : Prodrug-activating systems in suicide gene therapy. J Clin Invest2000; 105: 1161. Google Scholar 121 : The choice of prodrugs for gene directed enzyme prodrug therapy of cancer. Gene Ther1995; 2: 702. Google Scholar 122 : Prostate cancer gene therapy: herpes simplex virus thymidine kinase gene transduction followed by ganciclovir in mouse and human prostate cancer models. Hum Gene Ther1996; 7: 515. Google Scholar 123 : In vivo gene therapy for prostate cancer: preclinical evaluation of two different enzyme-directed prodrug therapy systems delivered by identical adenovirus vectors. Hum Gene Ther1998; 9: 1617. Google Scholar 124 : Adenovirus-mediated suicide-gene therapy using the herpes simplex virus thymidine kinase gene in cell and animal models of human prostate cancer: changes in tumour cell proliferative activity. BJU Int2000; 85: 759. Google Scholar 125 : Adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy leads to systemic activity against spontaneous and induced metastasis in an orthotopic mouse model of prostate cancer. Int J Cancer1997; 70: 183. Google Scholar 126 : Prodrug activation gene therapy and external beam irradiation in the treatment of prostate cancer. Urology1999; 54: 1098. Google Scholar 127 : Adenoviral transduction of a cytosine deaminase/thymidine kinase fusion gene into prostate carcinoma cells enhances prodrug and radiation sensitivity. Int J Cancer1999; 82: 293. Google Scholar 128 : Cooperative therapeutic effects of androgen ablation and adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy in experimental prostate cancer. Cancer Gene Ther1999; 6: 54. Google Scholar 129 : Cytopathic effect of in situ gene therapy in prostate cancer. Hum Pathol2000; 31: 866. Google Scholar 130 : Relative efficiency of tumor cell killing in vitro by two enzyme-prodrug systems delivered by identical adenovirus vectors. Clin Cancer Res1997; 3: 2075. Google Scholar 131 : In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial. Hum Gene Ther1999; 10: 1239. Google Scholar 132 : Suicide gene therapy toxicity after multiple and repeat injections in patients with localized prostate cancer. J Urol2000; 163: 1747. Abstract, Google Scholar 133 : Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell1996; 86: 353. Google Scholar 134 : The hallmarks of cancer. Cell2000; 100: 57. Google Scholar 135 : Tumor angiogenesis and endothelial cell modulatory factors. J Immunother1999; 22: 186. Google Scholar 136 : Tumor angiogenesis: biology and therapeutic prospects. In Vivo1998; 12: 563. Google Scholar 137 : Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science1999; 284: 808. Google Scholar 138 : Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature1997; 390: 404. Google Scholar 139 : Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell1997; 88: 277. Google Scholar 140 : Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med1996; 2: 689. Google Scholar 141 : Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. Science1999; 285: 1926. Google Scholar 142 : Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell1994; 79: 315. Google Scholar 143 : Adenovirus-mediated gene transfer of endostatin in vivo results in high level of transgene expression and inhibition of tumor growth and metastases. Proc Natl Acad Sci USA2000; 97: 4802. Google Scholar 144 : Viral vector-mediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth. Nat Med1997; 3: 437. Google Scholar 145 : Systemic delivery of antiangiogenic adenovirus AdmATF induces liver resistance to metastasis and prolongs survival of mice. Hum Gene Ther1999; 10: 3045. Google Scholar 146 : Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. Proc Natl Acad Sci USA1998; 95: 8795. Google Scholar 147 : Thyroid iodine transport. Thyroid2000; 10: 321. Google Scholar 148 : Treatment of prostate cancer by radioiodine after tissue-specific expression of the sodium iodide symporter. Cancer Res2000; 60: 6526. Google Scholar 149 : Adenovirus-mediated transfer of the thyroid sodium/iodide symporter gene into tumors for a targeted radiotherapy. Cancer Res2000; 60: 3484. Google Scholar 150 : Signaling pathway activated during apoptosis of the prostate cancer cell line LNCaP: overexpression of caspase-7 as a new gene therapy strategy for prostate cancer. Cancer Res1999; 59: 382. Google Scholar 151 : Adenoviral-mediated transfer of the TNF-related apoptosis-inducing ligand/Apo-2 ligand gene induces tumor cell apoptosis. J Immunol2000; 165: 2886. Google Scholar 152 : Intracellular fas ligand expression causes fas-mediated apoptosis in human prostate cancer cells resistant to monoclonal antibody-induced apoptosis. Mol Ther2000; 2: 348. Google Scholar 153 : Targeting and eradicating cancer cells by a prostate-specific vector carrying the diphtheria toxin A gene. Cancer Gene Ther2000; 7: 991. Google Scholar 154 : Fusogenic membrane glycoproteins as a novel class of genes for the local and immune-mediated control of tumor growth. Cancer Res2000; 60: 1492. Google Scholar 155 : Apoptosis or necrosis for tumor immunotherapy: what’s in a name?. J Mol Med1999; 77: 824. Google Scholar 156 : MHC class I and II expression in prostate carcinoma and modulation by interferon-alpha and -gamma. Prostate1997; 33: 233. Google Scholar 157 : Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc Natl Acad Sci USA1997; 94: 8099. Google Scholar 158 : Molecular characterization of defective antigen processing in human prostate cancer. J Natl Cancer Inst1995; 87: 280. Google Scholar 159 : Fas ligand is constitutively secreted by prostate cancer cells in vitro. Clin Cancer Res1998; 4: 1803. Google Scholar 160 : Fas-mediated apoptosis in human prostatic carcinoma cell lines. Cancer Res1997; 57: 1758. Google Scholar 161 : Immunotherapy for cancer by direct gene transfer into tumors. Hum Gene Ther1994; 5: 57. Google Scholar 162 : Experimental and clinical studies of cytokine gene-modified tumor cells. Hum Gene Ther1994; 5: 153. Google Scholar 163 : T-helper- and accessory-cell-independent cytotoxic responses to human tumor cells transfected with a B7 retroviral vector. Int J Cancer1994; 57: 754. Google Scholar 164 : The case for therapeutic vaccines. Melanoma Res1996; 6: 5. Google Scholar 165 : Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. Cancer Res1994; 54: 6228. Google Scholar 166 : Induction of potent antitumor natural killer cell activity by herpes simplex virus-thymidine kinase and ganciclovir therapy in an orthotopic mouse model of prostate cancer. Cancer Res1998; 58: 3221. Google Scholar 167 : Tissue-specific expression of the human prostate-specific antigen gene in transgenic mice: implications for tolerance and immunotherapy. Proc Natl Acad Sci USA1997; 94: 6369. Google Scholar 168 : Demonstration of a rational strategy for human prostate cancer gene therapy. J Urol1994; 151: 622. Link, Google Scholar 169 : Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res1999; 59: 5160. Google Scholar 170 : GM-CSF as a systemic adjuvant in a phase II prostate cancer vaccine trial. Prostate1999; 39: 291. Google Scholar 171 : Immunotherapy of prostate cancer in the Dunning rat model: use of cytokine gene modified tumor vaccines. Cancer Res1994; 54: 1760. Google Scholar 172 : Adenovirus-mediated interleukin-12 gene therapy for prostate cancer: suppression of orthotopic tumor growth and pre-established lung metastases in an orthotopic model. Gene Ther1999; 6: 338. Google Scholar 173 : Adenovirus-mediated expression of Fas ligand induces apoptosis of human prostate cancer cells. Cell Death Differ1999; 6: 175. Google Scholar 174 : Tumor necrosis factor-alpha-based gene therapy enhances radiation cytotoxicity in human prostate cancer. Cancer Gene Ther1998; 5: 344. Google Scholar 175 : Suppression of angiogenesis, tumorigenicity, and metastasis by human prostate cancer cells engineered to produce interferon-beta. Cancer Res1999; 59: 872. Google Scholar 176 : Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides. Prostate1998; 36: 39. Google Scholar From the Molecular Medicine Program and Department of Endocrinology, Mayo Clinic, Rochester, Minnesota© 2001 by American Urological Association, Inc.FiguresReferencesRelatedDetails Volume 166Issue 4October 2001Page: 1220-1233 Advertisement Copyright & Permissions© 2001 by American Urological Association, Inc.Keywordsprostategene therapyprostatic neoplasmsMetricsAuthor Information K.J. HARRINGTON More articles by this author C. SPITZWEG More articles by this author A.R. BATEMAN More articles by this author J.C. MORRIS More articles by this author R.G. VILE More articles by this author Expand All Advertisement PDF downloadLoading ..." @default.
• W2056531751 created "2016-06-24" @default.
• W2056531751 creator A5029309849 @default.
• W2056531751 creator A5042259851 @default.
• W2056531751 creator A5063630764 @default.
• W2056531751 creator A5070554485 @default.
• W2056531751 creator A5070640664 @default.
• W2056531751 date "2001-10-01" @default.
• W2056531751 modified "2023-09-27" @default.
• W2056531751 title "GENE THERAPY FOR PROSTATE CANCER: CURRENT STATUS AND FUTURE PROSPECTS" @default.
• W2056531751 cites W1489877664 @default.
• W2056531751 cites W1536673860 @default.
• W2056531751 cites W1542691850 @default.
• W2056531751 cites W1579297325 @default.
• W2056531751 cites W1607177619 @default.
• W2056531751 cites W1616824889 @default.
• W2056531751 cites W1899330274 @default.
• W2056531751 cites W1964465791 @default.
• W2056531751 cites W1964810515 @default.
• W2056531751 cites W1965634162 @default.
• W2056531751 cites W1970212185 @default.
• W2056531751 cites W1970239046 @default.
• W2056531751 cites W1971090459 @default.
• W2056531751 cites W1971189823 @default.
• W2056531751 cites W1971290197 @default.
• W2056531751 cites W1971629708 @default.
• W2056531751 cites W1972464496 @default.
• W2056531751 cites W1972601062 @default.
• W2056531751 cites W1978929016 @default.
• W2056531751 cites W1979063344 @default.
• W2056531751 cites W1979702687 @default.
• W2056531751 cites W1985804036 @default.
• W2056531751 cites W1986902003 @default.
• W2056531751 cites W1988211842 @default.
• W2056531751 cites W1988618456 @default.
• W2056531751 cites W1990439902 @default.
• W2056531751 cites W1992180249 @default.
• W2056531751 cites W1992602800 @default.
• W2056531751 cites W1995036338 @default.
• W2056531751 cites W1995293038 @default.
• W2056531751 cites W1998198136 @default.
• W2056531751 cites W2000615271 @default.
• W2056531751 cites W2002022916 @default.
• W2056531751 cites W2003797588 @default.
• W2056531751 cites W2005953810 @default.
• W2056531751 cites W2006149037 @default.
• W2056531751 cites W2006219146 @default.
• W2056531751 cites W2009068566 @default.
• W2056531751 cites W2009283811 @default.
• W2056531751 cites W2009761723 @default.
• W2056531751 cites W2010655741 @default.
• W2056531751 cites W2012053348 @default.
• W2056531751 cites W2013023284 @default.
• W2056531751 cites W2013474978 @default.
• W2056531751 cites W2013819225 @default.
• W2056531751 cites W2015809080 @default.
• W2056531751 cites W2015843087 @default.
• W2056531751 cites W2015911071 @default.
• W2056531751 cites W2016080258 @default.
• W2056531751 cites W2016358192 @default.
• W2056531751 cites W2021612058 @default.
• W2056531751 cites W2021875656 @default.
• W2056531751 cites W2026406742 @default.
• W2056531751 cites W2026757769 @default.
• W2056531751 cites W2027022352 @default.
• W2056531751 cites W2027430685 @default.
• W2056531751 cites W2027498717 @default.
• W2056531751 cites W2027555473 @default.
• W2056531751 cites W2028600721 @default.
• W2056531751 cites W2030599507 @default.
• W2056531751 cites W2031185644 @default.
• W2056531751 cites W2032611510 @default.
• W2056531751 cites W2034269086 @default.
• W2056531751 cites W2035067893 @default.
• W2056531751 cites W2040848265 @default.
• W2056531751 cites W2042105120 @default.
• W2056531751 cites W2042443815 @default.
• W2056531751 cites W2042946852 @default.
• W2056531751 cites W2043297474 @default.
• W2056531751 cites W2046895558 @default.
• W2056531751 cites W2047881598 @default.
• W2056531751 cites W2051331773 @default.
• W2056531751 cites W2054125735 @default.
• W2056531751 cites W2060910588 @default.
• W2056531751 cites W2066269784 @default.
• W2056531751 cites W2066415180 @default.
• W2056531751 cites W2067747515 @default.
• W2056531751 cites W2070805755 @default.
• W2056531751 cites W2071254628 @default.
• W2056531751 cites W2072068836 @default.
• W2056531751 cites W2072685184 @default.
• W2056531751 cites W2072928113 @default.
• W2056531751 cites W2073096708 @default.
• W2056531751 cites W2073134590 @default.
• W2056531751 cites W2073340988 @default.
• W2056531751 cites W2074870430 @default.
• W2056531751 cites W2075718053 @default.
• W2056531751 cites W2076674654 @default.

• next